98%
921
2 minutes
20
Activation of Src Family Kinase (SFK) signaling is required for the increase in endothelial permeability induced by a variety of cytokines and growth factors. However, we previously demonstrated that activation of endogenous SFKs by expression of dominant negative C-terminal Src Kinase (DN-Csk) is not sufficient to decrease endothelial adherens junction integrity. Basal SFK activity has been observed in normal venular endothelia and was not associated with increased basal permeability. The basal SFK activity however was found to contribute to increased sensitivity of the venular endothelium to inflammatory mediator-induced leakage. How SFK activation achieves this is still not well understood. Here, we show that SFK activation renders human dermal microvascular endothelial cells susceptible to low doses of TNF-α. Treatment of DN-Csk-expressing cells with 50 pg/ml TNF-α induced a loss of TEER as well as drastic changes in the actin cytoskeleton and focal adhesion proteins. This synergistic effect was independent of ROCK or NF-κB activity. TNF-α-induced p38 signaling was required for the synergistic effect on barrier function, and activation of the p38 MAPK alone was also able to induce changes in permeability only in monolayers with active SFKs. These results suggest that the activation of endogenous levels of SFK renders the endothelial barrier more susceptible to low, physiologic doses of TNF-α through activation of p38 which leads to a loss of endothelial tight junctions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014308 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161975 | PLOS |
Am J Dermatopathol
September 2025
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Background: Dermatologic adverse events (dAEs) are prevalent with BCR-ABL tyrosine kinase inhibitors (TKIs), affecting quality of life and treatment adherence. Despite their prevalence, underlying mechanisms of toxicity remain unclear. We sought to characterize dAEs across TKI generations to elucidate mechanisms driving toxicities.
View Article and Find Full Text PDFGene Expr Patterns
September 2025
Experimental Research Center, QingPu Hospital Affiliated to Fudan University, Shanghai, China.
The SH2B family, which includes SH2B1, SH2B2, and SH2B3, consists of adaptor proteins that possess conserved Src homology 2 (SH2) and pleckstrin homology (PH) domains, playing essential roles as signaling mediators. However, the gene expression patterns of this family during embryonic development are still mostly unclear. In this study, we first investigated the evolutionary conservation of SH2B across multiple species using phylogenetic analysis, which revealed high sequence homology between zebrafish Sh2b and its orthologs in other vertebrates.
View Article and Find Full Text PDFUnlabelled: Tyrosine kinases (TKs) are frequently mutated or overexpressed in cancer, and TK inhibitors (TKIs) are an important therapeutic modality against TK-driven cancers, but many patients show an underwhelming response to TKIs prescribed on the basis of tumor genotype. To find cell-intrinsic TK signaling patterns which might be predictive of poor response to TKI exposure, we used high-sensitivity multiplexed mass spectrometry to quantify endogenous levels of 1,222 phosphotyrosine (pY) sites across the proteomes of TK-driven human cancer cell lines with variable response to genotype-matched TKIs. In direct comparisons between TKI-tolerant and TKI-sensitive lines with a common driver TK, we found that TKI treatment was equally effective at blocking driver TK signaling, and higher basal activity of the driver TK did not always predict higher sensitivity to TKI.
View Article and Find Full Text PDFCell Signal
September 2025
Department of Oncology and Cancer Therapeutics Program, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address:
YES1 (Yamaguchi sarcoma virus homolog 1), a non-receptor tyrosine kinase of the SRC family (SFK), has been abnormally amplified or mutated in several types of solid tumors. The alteration of YES1 impacted multiple biological processes, including promoting tumor progression and metastasis, especially, producing cancer therapy resistance via bypass pathways. Thus, YES1 can serve as a druggable target to overcome drug resistance and suppress tumor growth.
View Article and Find Full Text PDFDrug Metab Dispos
July 2025
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Division of Molecular Biosciences, University at Buffalo, Buffalo, New York. Electronic address:
Src family kinases, including the Lck/Yes-related novel protein kinase (LYN), have emerged as posttranslational modulators of various transporters involved in clinically relevant pharmacokinetic drug-drug interactions. LYN expression was recently detected in hepatocytes, and we hypothesized that LYN deficiency alters the phosphorylation status and activity of transporters involved in hepatic drug disposition. An untargeted phospho-proteomic screen in livers of mice revealed that LYN deficiency was associated with significantly reduced phosphorylation of the hepatic uptake organic anion transporting polypeptide Oatp1b2 transporter that recognizes a wide range of structurally diverse xenobiotics.
View Article and Find Full Text PDF